Latest Oncology News

ADAURA, Explosion of Targeted Agents Underscore Need for Molecular Testing in Lung Cancer

ADAURA, Explosion of Targeted Agents Underscore Need for Molecular Testing in Lung Cancer

June 15th 2021

Courtney Marabella

The data from the phase 3 ADAURA trial with adjuvant osimertinib are among the most significant to read out in the past year in the realm of non–small cell lung cancer.

Iomab-B Continues to Showcase Impressive Bone Marrow Transplant and Engraftment Rate in Relapsed/Refractory AML

Iomab-B Continues to Showcase Impressive Bone Marrow Transplant and Engraftment Rate in Relapsed/Refractory AML

June 15th 2021

Gina Mauro

Iodoine apamistamab, a radiotherapy that targets CD45-expressing cells, demonstrated a 100% bone marrow transplant and engraftment rate in patients with relapsed/refractory acute myeloid leukemia vs 18% for those who received a physician’s choice of salvage treatment.

Investigators Set Sights on Curative Approaches for Follicular Lymphoma

Investigators Set Sights on Curative Approaches for Follicular Lymphoma

June 15th 2021

Christina Loguidice

The majority of patients with indolent follicular lymphoma do well with observation and after first-line treatment, but approximately 20% experience disease progression within 2 years of their initial treatment, which is associated with a 50% risk of dying within 5 years. Subsequently, this is an area of unmet need but one in which considerable progress is being made.

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma

June 15th 2021

Jessica Hergert

James A. DeCaprio, MD, discusses the incidence of Merkel cell carcinoma, risk factors for the disease, established treatment options, and investigational regimens on the horizon.

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

June 15th 2021

As the treatment landscape for ALK-positive metastatic non-small cell lung cancer continues to take shape, extended analyses of clinical trial data may offer additional clinical insight on the utility of approved therapies.

Latest Oncology Videos

All Oncology News

Kaiku Health and Novartis Collaborate on Specialized Digital Patient Monitoring Technology

June 15th 2021

Kyle Doherty

Kaiku Health has announced that they are partnering with the global healthcare company Novartis to develop a digital patient monitoring and management system specifically for patients with melanoma who are receiving BRAF/MEK combination therapies.

Burgeoning Breast Cancer Landscape Brings Hope for a Brighter Future

June 15th 2021

Caroline Seymour

The expansion of HER2-directed treatments and formulations, the availability of CDK4/6 inhibitors, and the broad activity of sacituzumab govitecan-hziy is a testament to the successful development of personalized medicine in breast cancer.

The Next Chapter in RCC Recontextualizes Treatment Considerations

June 15th 2021

Saby George, MD, FACP, Roswell Park

Renal cell carcinoma is one of the top 10 most common cancers, although incidence rates have been stable over the past decade. It is more common in men than women and rates are higher among African American, American Indian, and Alaska Native patient populations.

An Expert Provides Insight Into the Use of BTK Inhibitors in CLL

June 15th 2021

Caroline Seymour

Parameswaran Venugopal, MD, discussed the toxicity profiles of BTK inhibitors regarding treatment selection in CLL.

eMonarcHER to Examine Abemaciclib Plus Adjuvant Endocrine Therapy in HER2+ Early Breast Cancer

June 14th 2021

Kristi Rosa

The safety and efficacy of abemaciclib will be examined in patients with hormone receptor–positive, HER2-positive, node-positive, high-risk early breast cancer who have completed standard adjuvant HER2-targeted treatment as part of the phase 3 eMonarcHER trial.

Rituximab Biosimilar CT-P10 Demonstrates Real-World Safety, Efficacy in DLBCL

June 14th 2021

Kristi Rosa

The rituximab biosimilar CT-P10 produced response and survival rates that were comparable to those previously reported with the reference product, along with acceptable tolerability, in patients with diffuse large B-cell lymphoma.

Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer

June 14th 2021

OncLive Staff

Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.

Water Vapor Ablation Therapy Shows Encouraging Efficacy, Safety in Prostate Cancer

June 14th 2021

Kristi Rosa

A water vapor ablation therapy has been shown to be able to reach and treat all prostate regions and eradicate intermediate risk, grade group 2 prostate cancer with acceptable safety and tolerability.

Front-MIND Aims to Examine Tafasitamab Triplet in DLBCL

June 14th 2021

Kyle Doherty

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.

Frontline Trastuzumab Deruxtecan Under Exploration With or Without Pertuzumab in HER2+ Breast Cancer

June 14th 2021

Kristi Rosa

Fam-trastuzumab deruxtecan-nxki is under investigation with or without pertuzumab vs a standard-of-care regimen comprised of a taxane, trastuzumab, and pertuzumab in the frontline treatment of patients with HER2-positive metastatic breast cancer as part of the phase 3 DESTINY-Breast09 trial.

ADCs Show Promise in NSCLC But Have a Long Road Ahead

June 14th 2021

Brittany Lovely

The potential role for antibody-drug conjugates for treating patients with non–small cell lung cancer continues to evolve as new data challenge investigators to reexamine their approaches.

Adjuvant Nivolumab Improves DFS in High-Risk Muscle-Invasive Urothelial Cancer

June 14th 2021

Caroline Seymour

Adjuvant nivolumab led to a significant improvement in disease-free survival compared with placebo in patients with high-risk muscle-invasive urothelial carcinoma following radical surgery, irrespective of PD-L1 expression level.

Deep Responses Yielded With Daratumumab Plus CyBorD Followed by Daratumumab Maintenance in Multiple Myeloma

June 14th 2021

Matthew Fowler

For patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status, daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses.

Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Kristie L. Kahl

Ciltacabtagene autoleucel continued to yield early, deep, and durable responses after longer follow-up in patients with relapsed/refractory multiple myeloma.

Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Brielle Benyon

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

See All News